|Title: ||Synergistic antitumour effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype.|
|Citation: ||Oncology Reports, 9(2): 379-382|
|Publisher: ||Spandidos Publications Ltd|
|Journal: ||Oncology Reports|
|Issue Date: ||2002 |
|PubMed ID: ||11836612|
|Additional Links: ||http://www.spandidos.com/or/|
|Abstract: ||We investigated the effect of toremifene, interferon-alpha2a, interferon-alpha2b and interferon-alpha2c, singly and in combination for their effect on the growth of ZR-75-1 human breast cancer cells. Median effect analysis was used to determine synergistic or additive effects. Anti-proliferative studies showed that the growth of ZR-75-1 cells was inhibited to a greater extent by combination treatment with toremifene plus interferon-alpha2a, resulting in a synergistic interaction (CI <1) for all concentrations tested. A combination of toremifene plus interferon-alpha2b resulted in a synergistic interaction (CI <1) for the two highest concentrations of toremifene (10(-6) and 10(-7) M) and an additive effect (CI approximately equal to 1) for the lower concentrations (10(-8) to 10(-10) M). When toremifene was combined with interferon-alpha2c no additive or synergistic interaction was determined.|
|MeSH: ||Antineoplastic Agents, Hormonal|
Antineoplastic Combined Chemotherapy Protocols
Dose-Response Relationship, Drug
Tumor Cells, Cultured
|Appears in Collections: ||Cancer Research Group|
|Files in This Item:|
There are no files associated with this item.
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.